CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Caris Life Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$30.71+0.15 (+0.49%)
Close on Oct 19, 2026
- Market cap
- $8.69B
- P/E (TTM)
- –
- Dividend yield
- –
Caris Life Sciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of services - Molecular profiling services | $252.25M | $210.80M | $282.13M | $207.59M | $162.92M | $114.08M | $94.42M | $93.80M | $87.66M | 95.7% | +54.8% |
| Cost of services - Pharma research and development services | $11.46M | $5.37M | $10.76M | $9.25M | $18.47M | $6.83M | $35.49M | $7.82M | $12.39M | 4.3% | -38.0% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $261.57M | $213.84M | $291.23M | $213.55M | $178.18M | $118.43M | $126.62M | $99.40M | $97.38M | 99.2% | +46.8% |
| International | $2.14M | $2.34M | $1.65M | $3.28M | $3.22M | $2.48M | $3.29M | $2.22M | $2.67M | 0.8% | -33.6% |
From the segment and revenue-disaggregation notes of Caris Life Sciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.